NCT01364779

Completed

Prevalence of Aspirin Resistance in Chronic Kidney Disease P...

Northwell Health Source

Compare

Other study identifiers

Sponsor study identifier

10-025

Study Type

observational

Actual enrollment (reported)

15

Locations

1 country

Sites

1

Timeline

Study Start

April 2010

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

March 2012

Actual (reported)

Study Completion

March 2012

Actual (reported)

Brief Summary

The primary objective of the study is to determine the prevalence of aspirin resistance in chronic kidney disease patients. The secondary objectives are to determine possible risk factors contributing to aspirin resistance in this population.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 15 participants
Study completion date: March 2012
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
April 2010
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
May 27, 2011
Actual (reported)
First Posted
June 2, 2011
Actual (reported)
Primary Completion
March 2012
Actual (reported)
Study Completion
March 2012
Actual (reported)

Last Updated: May 15, 2013
Status Verified: May 2013
Last Update Submitted: May 14, 2013

Conditions

Chronic Kidney Disease

Keywords

aspirinChronic kidney disease

Outcome Measures

Primary Outcomes (1)

prevalence of aspirin resistance in chronic kidney disease patients
Blood drawn for the Accumetric test
2 years

Secondary Outcomes (1)

risk factors contributing to aspirin resistance in this population.
2 years

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

Patients presenting to the nephrology clinic at SIUH and the nephrology clinic at Staten Island rehab and the admitted patients who give consent.

You may qualify if:

Patients with known structural kidney disease as evident by history or by urinalysis and CKD stage III or IV determined by MDRD formula and who are taking aspirin.

Sponsors & Collaborators

Northwell Health
Otherlead
Staten Island University Hospital
Othercollaborator

Study Sites (1)

staten island University Hospital nephrology clinic

Staten Island, New York, 10305, United States

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood draw

MeSH Terms

Conditions

Renal Insufficiency, Chronic

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

Suzanne El_Sayegh, MD
Staten Island University Hospital
PRINCIPAL INVESTIGATOR

Enrollment

15 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: CASE CONTROL
Time Perspective: CROSS SECTIONAL
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Nephrology Attending, Assoc. Chair of Medicine

Study Record Dates

First Submitted

May 27, 2011

First Posted

June 2, 2011

Study Start

April 2010

Date type not reported

This date has not been verified as actual or estimated.

NCT00769834

Disc Edema in Patients With Chronic Kidney Disease

Withdrawn

NCT04707573

Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4

Phase 2Completed

NCT00994838

Reduced Calorie Diet Intervention in Kidney Transplant Recipients

Phase 2Completed

NCT01161407

Calcium and Phosphorus Balance and Calcium Kinetics in Patients With Stage 3/4 Chronic Kidney Disease

Not ApplicableCompleted

NCT00793806

Immunologic Abnormalities, Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease

Completed

NCT01150851

Oxidative Stress in Chronic Kidney Disease: Diet and Exercise

Not ApplicableCompleted

You may not qualify if:

Younger than 18 years of age.
Bleeding disorder or myeloproliferative disorders.
Thrombocytopenia with platelets \< 100.000.
Malignancy.
Acute hemorrhagic disease.
A recent history of receipt of platelet glycoprotein IIb/IIIa blockers.
Liver disease as evident by abnormal liver function and total bilirubin \> 2mg/dl.
use of anticoagulation.

Contact the study team to confirm eligibility.

Primary Completion

March 2012

Actual (reported)

Study Completion

March 2012

Actual (reported)

Last Updated

May 15, 2013

Record last verified: 2013-05

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT01364779
Data provider: ClinicalTrials.gov
Source updated: 2013-05-15
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:36:58 UTC

Locations

US(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations